NEW YORK, April 11, 2023 /PRNewswire/ -- The human papillomavirus (HPV) therapeutics market size is forecasted to increase by USD 953.3 million from 2022 to 2027, at a CAGR of 5.15%, according to a recent market study by Technavio. The growth of the market will be driven by the advent of vaccines, the development of oral vaccines for HPV, and strong disease progression. Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download the Sample Report
Vendor Analysis
The global human papillomavirus (HPV) therapeutics market is concentrated due to the limited number of vendors and treatment options. The market has only three approved vaccines and three drugs for treating indications caused by HPV. Merck Sharp and Dohme Corps GARDASIL and GARDASIL 9 are two major vaccines that contribute to the market. Merck Sharp and Dohme Corp. dominate the market with the largest market share. The dominance of these vendors is expected to continue during the forecast period. Competition among vendors is high from generic and biosimilar products as they lose patent protection. Increased brand awareness has intensified the competition in therapeutic areas important to vendors' long-term business performance. The launch of novel therapies is expected to increase the competition among vendors in the market and may result in vendor fragmentation during the forecast period.
2A Pharma ApS, AbbVie Inc., Bavarian Nordic AS, BioVaxys Technology Corp., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ISA Pharmaceuticals BV, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Xiamen Innovax Biotech Co. Ltd., Merck and Co. Inc., Bausch Health Co. Inc., and Inovio Pharmaceuticals Inc. are some of the key vendors covered in the report.
Why Buy?
- Add credibility to strategy
- Analyzes competitor's offerings
- Get a holistic view of the market
Grow your profit margin with Technavio - Buy the Report
Key Benefits for Industry Players & Stakeholders –
- The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
- It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
- The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Get a holistic overview of the human papillomavirus (HPV) therapeutics market by
industry experts to evaluate and develop growth strategies. Download the Sample Report
Market Segmentation:
The market is segmented by route of administration (parenteral and topical), indication (cervical cancer, anal cancer, vulvar and vaginal cancer, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
- By route of administration, the market growth in the parenteral segment will be significant during the forecast period. The market has several vaccines in the pipeline that are being developed for being administered through the parenteral route. In addition, the increasing awareness about HPV and the strong efficacy of vaccines toward potentially preventing HPV from progressing into cancer or other indications are driving the growth of the segment.
- By indication, the market growth will be significant in the cervical cancer segment during the forecast period. The prevalence of cervical cancer is growing steadily across the world. This has created a demand for cervical cancer diagnostics testing products. Hence, vendors are developing automated systems for HPV testing, which can perform tests in 30-60 minutes and provide high-quality results. Vendors are also adopting various strategies to develop innovative devices to ensure product differentiation and sustain market competition. Such factors are driving the growth of the segment.
- North America will account for 50% of the market growth during the forecast period. Factors such as the high sales of approved therapeutics and vaccines and the strong prevalence of various types of HPV are driving the growth of the regional market. Other factors contributing to the growth of the HPV therapeutics market in North America include the rise in the prevalence of sexually transmitted diseases (STDs), the rise in healthcare expenditure, and an increase in the number of advanced healthcare facilities.
Market Dynamics:
Key Drivers:
- Advent of vaccines
- Development of oral vaccines for HPV
- Strong disease progression
The market is witnessing significant improvements in the research and development of highly advanced vaccines with a longer half-life. The market currently consists of three approved vaccines, namely GARDASIL, GARDASIL 9, and CERVARIX, for HPV. The high efficacy of these vaccines has encouraged vendors to conduct research on vaccines for the prevention and treatment of HPV. For instance, MedImmune, a subsidiary of AstraZeneca, is currently conducting research on the development of the MEDI0457 vaccine for the treatment of cervical cancer and head and neck cancer caused by HPV type 16 and type 18. The vaccine is currently in Phase II of clinical trials and is expected to get marketing approval over the forecast period. The increasing R&D on the development of such drugs will drive the growth of the market.
Major Trends:
- R&D of new drugs for Orthostatic Hypotension (OH) treatment
- Use of combination therapy in OH treatment
- Adoption of fludrocortisone as off-label first-line pharmacotherapy
The lack of approval with substantial clinical efficiency has created a high unmet demand for OH drugs. This has increased efforts in R&D to develop novel vaccines to cater to the unmet need in OH pharmacological therapy. For instance, Lundbeck LLC conducted Phase IV clinical trials in the US to assess the sustained effects of droxidopa therapy in patients with OH. The study was completed in December 2020. Similarly, Theravance Biopharma Inc. is developing ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor, to treat patients with symptomatic OH. In April 2022, the company announced the positive topline 16-week data from the Phase III clinical trial of ampreloxetine for the treatment of symptomatic OH. Such developments will positively influence the growth of the market.
Key Challenges:
- Lack of curative therapies
- Anti-vaxxer movement
- Multiple-dose schedules of vaccines
Despite the availability of vaccines to prevent the progression of HPV into cancer, the market still faces a shortage of curative therapies. Approved vaccines only reduce the risk of getting affected with HPV and do not ensure complete avoidance of the virus. Thus, the market is witnessing increased preference for alternative treatment options such as radiation therapy and cryotherapy among patients. These factors will reduce the growth potential of the market.
What are the key data covered in this human papillomavirus (HPV) therapeutics market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the human papillomavirus (HPV) therapeutics market between 2023 and 2027
- Precise estimation of the size of the human papillomavirus (HPV) therapeutics market size and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the human papillomavirus (HPV) therapeutics market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of human papillomavirus (HPV) therapeutics market vendors
Gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Related Reports:
- The cytomegalovirus (CMV) therapeutics market size is expected to increase by USD 332.21 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. The market is segmented by route of administration (oral, parenteral, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
- The antimicrobial therapeutics market is estimated to grow at a CAGR of 5.63% between 2023 and 2027. The size of the market is forecasted to increase by USD 51.4 billion. The market is segmented by application (antiviral, antibacterial, antifungal, and antiparasitic), end-user (pharmacies, hospitals and clinics, and research and academic institutes), and Geography (North America, Europe, Asia, and Rest of World (ROW)).
Human Papillomavirus (HPV) Therapeutics Market Scope |
|
Report Coverage |
Details |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.15% |
Market growth 2023-2027 |
USD 953.3 million |
Market structure |
Concentrated |
YoY growth 2022-2023 (%) |
4.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 50% |
Key countries |
US, Canada, Brazil, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
2A Pharma ApS, AbbVie Inc., Bavarian Nordic AS, BioVaxys Technology Corp., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ISA Pharmaceuticals BV, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Xiamen Innovax Biotech Co. Ltd., Merck and Co. Inc., Bausch Health Co. Inc., and Inovio Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse through Technavio's Health Care Market Reports
Table of contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Indication
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global Human Papillomavirus (HPV) therapeutics market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global Human Papillomavirus (HPV) therapeutics market 2017 - 2021 ($ million)
- 4.2 route of administration Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – route of administration Segment 2017 - 2021 ($ million)
- 4.3 Indication Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Indication Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Route of Administration
- 6.1 Market segments
- Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
- 6.2 Comparison by Route of Administration
- Exhibit 32: Chart on Comparison by Route of Administration
- Exhibit 33: Data Table on Comparison by Route of Administration
- 6.3 Parenteral - Market size and forecast 2022-2027
- Exhibit 34: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
- 6.4 Topical - Market size and forecast 2022-2027
- Exhibit 38: Chart on Topical - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Topical - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Topical - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Topical - Year-over-year growth 2022-2027 (%)
- 6.5 Market opportunity by Route of Administration
- Exhibit 42: Market opportunity by Route of Administration ($ million)
- Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Indication
- 7.1 Market segments
- Exhibit 44: Chart on Indication - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Indication - Market share 2022-2027 (%)
- 7.2 Comparison by Indication
- Exhibit 46: Chart on Comparison by Indication
- Exhibit 47: Data Table on Comparison by Indication
- 7.3 Cervical cancer - Market size and forecast 2022-2027
- Exhibit 48: Chart on Cervical cancer - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Cervical cancer - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Cervical cancer - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Cervical cancer - Year-over-year growth 2022-2027 (%)
- 7.4 Anal cancer - Market size and forecast 2022-2027
- Exhibit 52: Chart on Anal cancer - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Anal cancer - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Anal cancer - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Anal cancer - Year-over-year growth 2022-2027 (%)
- 7.5 Vulvar and vaginal cancer - Market size and forecast 2022-2027
- Exhibit 56: Chart on Vulvar and vaginal cancer - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Vulvar and vaginal cancer - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Vulvar and vaginal cancer - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Vulvar and vaginal cancer - Year-over-year growth 2022-2027 (%)
- 7.6 Others - Market size and forecast 2022-2027
- Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)
- 7.7 Market opportunity by Indication
- Exhibit 64: Market opportunity by Indication ($ million)
- Exhibit 65: Data Table on Market opportunity by Indication ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 Germany - Market size and forecast 2022-2027
- Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.9 Canada - Market size and forecast 2022-2027
- Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
- 9.10 China - Market size and forecast 2022-2027
- Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.11 Brazil - Market size and forecast 2022-2027
- Exhibit 103: Chart on Brazil - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on Brazil - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on Brazil - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on Brazil - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 112: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 113: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification
- 12.3 2A Pharma ApS
- Exhibit 115: 2A Pharma ApS - Overview
- Exhibit 116: 2A Pharma ApS - Product / Service
- Exhibit 117: 2A Pharma ApS - Key offerings
- 12.4 AbbVie Inc.
- Exhibit 118: AbbVie Inc. - Overview
- Exhibit 119: AbbVie Inc. - Product / Service
- Exhibit 120: AbbVie Inc. - Key news
- Exhibit 121: AbbVie Inc. - Key offerings
- 12.5 Bausch Health Co. Inc.
- Exhibit 122: Bausch Health Co. Inc. - Overview
- Exhibit 123: Bausch Health Co. Inc. - Business segments
- Exhibit 124: Bausch Health Co. Inc. - Key news
- Exhibit 125: Bausch Health Co. Inc. - Key offerings
- Exhibit 126: Bausch Health Co. Inc. - Segment focus
- 12.6 Bavarian Nordic AS
- Exhibit 127: Bavarian Nordic AS - Overview
- Exhibit 128: Bavarian Nordic AS - Product / Service
- Exhibit 129: Bavarian Nordic AS - Key offerings
- 12.7 BioVaxys Technology Corp.
- Exhibit 130: BioVaxys Technology Corp. - Overview
- Exhibit 131: BioVaxys Technology Corp. - Product / Service
- Exhibit 132: BioVaxys Technology Corp. - Key offerings
- 12.8 F. Hoffmann La Roche Ltd.
- Exhibit 133: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 134: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 135: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 136: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 137: F. Hoffmann La Roche Ltd. - Segment focus
- 12.9 GlaxoSmithKline Plc
- Exhibit 138: GlaxoSmithKline Plc - Overview
- Exhibit 139: GlaxoSmithKline Plc - Business segments
- Exhibit 140: GlaxoSmithKline Plc - Key offerings
- Exhibit 141: GlaxoSmithKline Plc - Segment focus
- 12.10 Inovio Pharmaceuticals Inc.
- Exhibit 142: Inovio Pharmaceuticals Inc. - Overview
- Exhibit 143: Inovio Pharmaceuticals Inc. - Product / Service
- Exhibit 144: Inovio Pharmaceuticals Inc. - Key news
- Exhibit 145: Inovio Pharmaceuticals Inc. - Key offerings
- 12.11 ISA Pharmaceuticals BV
- Exhibit 146: ISA Pharmaceuticals BV - Overview
- Exhibit 147: ISA Pharmaceuticals BV - Product / Service
- Exhibit 148: ISA Pharmaceuticals BV - Key offerings
- 12.12 Merck and Co. Inc.
- Exhibit 149: Merck and Co. Inc. - Overview
- Exhibit 150: Merck and Co. Inc. - Business segments
- Exhibit 151: Merck and Co. Inc. - Key news
- Exhibit 152: Merck and Co. Inc. - Key offerings
- Exhibit 153: Merck and Co. Inc. - Segment focus
- 12.13 Serum Institute of India Pvt. Ltd.
- Exhibit 154: Serum Institute of India Pvt. Ltd. - Overview
- Exhibit 155: Serum Institute of India Pvt. Ltd. - Product / Service
- Exhibit 156: Serum Institute of India Pvt. Ltd. - Key offerings
- 12.14 Walvax Biotechnology Co. Ltd.
- Exhibit 157: Walvax Biotechnology Co. Ltd. - Overview
- Exhibit 158: Walvax Biotechnology Co. Ltd. - Product / Service
- Exhibit 159: Walvax Biotechnology Co. Ltd. - Key offerings
- 12.15 Xiamen Innovax Biotech Co. Ltd.
- Exhibit 160: Xiamen Innovax Biotech Co. Ltd. - Overview
- Exhibit 161: Xiamen Innovax Biotech Co. Ltd. - Product / Service
- Exhibit 162: Xiamen Innovax Biotech Co. Ltd. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 163: Inclusions checklist
- Exhibit 164: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 165: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 166: Research methodology
- Exhibit 167: Validation techniques employed for market sizing
- Exhibit 168: Information sources
- 13.5 List of abbreviations
- Exhibit 169: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article